Effectiveness of local anesthesia in pain reduction after bilateral surgery of hallux valgus

2017 ◽  
Vol 23 ◽  
pp. 64-65
Author(s):  
T. Bienek
2021 ◽  
Vol 14 (4) ◽  
pp. 462-466
Author(s):  
B Sandhyarani ◽  
Mital V Kevadia ◽  
Anil T Patil ◽  
Ramoli R Pawar

1992 ◽  
Vol 3 (1) ◽  
pp. 107-109 ◽  
Author(s):  
Josiah W. Bancroft ◽  
James F. Benenati ◽  
Gary J. Becker ◽  
Barry T. Katzen

2014 ◽  
Vol 5 (2) ◽  
pp. 129-133
Author(s):  
Vikas Bendgude ◽  
Hrishikesh Walimbe ◽  
Mohammed Nadeem Ahmed Bijle ◽  
Sneha Muchandi ◽  
Rahul Deshpande ◽  
...  

ABSTRACT Introduction Pain control is an integral part of modern dentistry. Needle injection of local anesthetic which is the commonest modality of pain control itself proves to be painful for the child. Hence, it is important for the pediatric dentists to resort to a pain free method of administering local anesthesia for a patient. Topical anesthetics have proven to reduce the pain experience during administration of local anesthetic injection. The aim of this study is to evaluate and compare the efficacy of two topical anesthetic agents—EMLA 5% cream (Eutectic mixture of local anesthetics—Lignocaine 2.5% and prilocaine 2.5%) and Benzocaine 20% gel in reducing the pain during administration of local anesthetic injection in children. Materials and methods EMLA 5% cream and Benzocaine 20% gel were used in the study. Children from mixed dentition age group between 6 and 9 years of age were selected. The two selected topical anesthetics were applied on buccal mucosa at two different appointments in a given child, following which the local anesthetic was administered on the test site. The pain responses of the child were evaluated using the Wong Baker Faces Pain Rating Scale. The results were then statistically analyzed using Mann-Whitney U-test. Results EMLA 5% cream was three times highly effective in pain reduction than Benzocaine 20% gel. Conclusion EMLA 5% cream is comparatively better than benzocaine 20% gel with regards to pain reduction during the administration of local anesthetic injection in children. How to cite this article Walimbe H, Muchandi S, Bijle MNA, Bendgude V, Deshpande R, Dolas A, Chaturvedi S. Comparative Evaluation of the Efficacy of Topical Anesthetics in Reducing Pain during Administration of Injectable Local Anesthesia in Children. World J Dent 2014;5(2):129-133.


2014 ◽  
Vol 7 (S2) ◽  
Author(s):  
Irvine Nake ◽  
Derek Santos ◽  
Gary Boon ◽  
Francis Babi ◽  
David Cartwright ◽  
...  
Keyword(s):  

2020 ◽  
Vol 5 (2) ◽  
pp. 2473011420S0000
Author(s):  
Sara H. Galli ◽  
Nicholas Johnson ◽  
W. Hodges Davis ◽  
Robert B. Anderson ◽  
Carroll P. Jones ◽  
...  

Category: Bunion; Midfoot/Forefoot Introduction/Purpose: Treatment for symptomatic hallux valgus encompasses a spectrum of surgical options to appropriately address the degree of deformity. The modified Lapidus has emerged as a powerful surgical option to address moderate to severe deformity as well as hallux valgus with 1st ray hypermobility. Unlike metatarsal osteotomies, the literature is lacking in clinical and radiographic outcomes. Previous retrospective series have reported recurrence rates less than 15%, but our experience suggested recurrence rates were higher. Methods: After obtaining institutional board review approval, patients were identified by procedural billing codes from 2012- 2016. Only patients who underwent a primary Lapidus surgery with greater than 1 year radiographic follow-up were included. Larger midfoot fusions and flatfoot reconstructions were excluded. Charts were reviewed to identify complications and reoperations. Radiographs were reviewed and HVA, IMA, sesamoid position (0-4), and Meary’s angle measured on preoperative, 1st weigh-bearing post-operative, and final follow-up radiographs. Data was analyzed utilizing statistical analysis software (SAS v9.4). Results: 114 patients were identified with 12 undergoing bilateral surgery (126 surgeries). There were 106 females and 8 males, and median age was 57.5 years at time of surgery. Median follow-up from index surgery was 2.9 years. Using HVA>=20 as cutoff for recurrence, 58 (46%) recurrences were identified, but only 15 (12%) underwent revision surgery. There were 32 total reoperations, including 8 nonunions ( table 1A ). Median preoperative HVA was greater in group with recurrence than group without recurrence (38 vs 30, p<0.0001, table 1B ). In addition, less correction of HVA and IMA was seen in group with recurrence (ΔHVA=20 vs 22, p<0.0001; ΔIMA 6 vs 9, p<0.0001, table 1B ). When there was recurrence at final follow-up, it appears corrected IMA was maintained while HVA increased (ΔIMA=2, ΔHVA=10, table 1B ). We used a receiver operative curve (ROC) to define the HVA cut-off of HVA>=30 with an AUC of 0.75. That indicated that in 75% of cases, preoperative HVA>=30 predicted recurrence. We identified that HVA<30 has a reduced odds of recurrence (OR=0.165; 95% CI=0.062-0.536). Preoperative IMA and arch alignment were not associated with risk of recurrence ( table 1C ). [Table: see text] Conclusion: As has been determined in other hallux valgus series evaluating metatarsal osteotomies, increased HVA>=30 is a risk factor for recurrence. Despite being acknowledged as a powerful operation for hallux valgus correction, the modified Lapidus still had a high rate (46%) of radiographic recurrence when used to treat severe deformity. However, only 12% underwent revision surgery in our series. This is important when counseling patients before surgery as the modified Lapidus operation does not obviate the risk of recurrence as has been previously suggested, but the lower revision rate suggests radiographic outcomes alone do not drive satisfaction. Further outcome measures are needed on this cohort to better identify surgical variables associated with maintained correction, other risk factors for recurrence, as well as patient reported outcomes.


2020 ◽  
Vol 5 (4) ◽  
pp. 2473011420S0044
Author(s):  
Robert Silva ◽  
Selene G. Parekh ◽  
Lawrence A. DiDomenico ◽  
David G. Armstrong ◽  
Babak Baravarian ◽  
...  

Category: Bunion Introduction/Purpose: Hallux valgus (HV) is a progressive foot deformity affecting nearly 25% of adults, characterized by pain and functional disability, and morphological changes in foot appearance due to progressive lateral deviation of the hallux. HV is initially managed with orthotic interventions, which are often ineffective. Corrective surgery can be efficacious, but is associated with significant pain, long recovery times and, potentially, recurrence. AbobotulinumtoxinA (aboBoNT-A, Dysport®) injections may correct the underlying muscle imbalance (resulting from hypertonia of specific forefoot muscles governing the hallux) thought to cause deformity, thereby reducing pain and disability associated with HV. Therefore, the aim of this phase II, placebo-controlled, parallel-group, multicenter study (NCT03569098) was to evaluate the effect of aboBoNT-A on pain and disability associated with HV in adults. Methods: Patients were randomized (1:1:1) to receive aboBoNT-A 300U, 500U, or placebo in a ≥12-week double-blind (DB) phase, followed by a 24-week open-label (OL) phase (OL Cycle 1, 300U [all patients]; OL Cycle 2, 300U or 500U). Total doses were divided equally into four specific foot muscles involved in hallux function. Eligible patients were aged 18–75 years with an HV angle 15–30° and numeric pain rating scale (NPRS) score of ≥4 (0, no pain; 10, worst possible pain). NPRS score was self-reported for 7 days before baseline and before each post-baseline visit. The primary endpoint was change from baseline in NPRS score (7- day average) before DB Week 8. Two post-hoc endpoints were defined as the percentage of days patients’ NPRS scores were: 1) lower than their lowest NPRS score before baseline; and 2) ≥2 points lower than mean baseline NPRS score. Adverse events (AEs) were monitored throughout the study. Results: No statistically significant differences were observed for aboBoNT-A 300U (n=63) or 500U (n=60) versus placebo (n=63) in NPRS scores at DB Week 8 (least squares mean [standard error]: -1.7 [0.3], -2.4 [0.3], versus -2.0 [0.3], respectively). Scores showed a trend towards pain reduction at Week 12 for aboBoNT-A 500U (-2.4 [0.3]) versus placebo (-1.7 [0.3]; p=0.06). Scores reduced further in OL Cycle 1. Post-hoc analyses showed that patients treated with aboBoNT-A 500U spent significantly more days with reduced pain before DB Week 8 compared with those treated with placebo: analysis 1) 63% versus 38% of days, respectively (p<0.01); analysis 2) 55% versus 37% of days, respectively (p=0.06). Results were similar at DB Week 12 (analysis 1: p<0.01; analysis 2: p=0.02, respectively). No new or unexpected AEs were reported. Conclusion: Although the primary endpoint was not met at Week 8, a trend towards significant pain reduction versus placebo was reported for patients with HV at Week 12 following aboBoNT-A 500U injection. Pain was further reduced with repeat injection. Post-hoc analyses indicate that HV patients spent a greater proportion of time with reduced pain following aboBoNT-A 500U injection compared with placebo. This may be a more clinically relevant assessment of benefit than NPRS score averaged over 7 days. Safety results were in line with the known profile of aboBoNT-A.


Sign in / Sign up

Export Citation Format

Share Document